Martin Vincent, Riffaud Armance, Marday Tevrasamy, Brouillard Charly, Franc Bernard, Tassin Jean-Pol, Sevoz-Couche Caroline, Mongeau Raymond, Lanfumey Laurence
Inserm UMR S894, Centre de Psychiatrie et Neuroscience, Université Paris Descartes, Paris, France.
Inserm UMR S1158, Neurophysiologie Respiratoire Expérimentale et Clinique, Université Pierre et Marie Curie, Paris, France.
Br J Pharmacol. 2017 Aug;174(15):2471-2483. doi: 10.1111/bph.13857. Epub 2017 Jul 5.
It has recently been suggested that 5-HT receptor blockade enhances the efficacy of selective 5-HT (serotonin) reuptake inhibitor (SSRI) antidepressants and may reverse stress-induced deficits in rodents.
To further explore this hypothesis, we used mice lacking the 5-HT receptor (Htr3a KO) and their wild-type (WT) controls to assess their response in behavioural paradigms relevant to anxiety and depression. Mice were studied under basal, antidepressant treatments and chronic social defeat stress (CSDS) conditions.
In basal conditions, Htr3a KO mice displayed anxiolytic- and antidepressant-like behaviours in the elevated plus maze, the social interaction and the forced swim tests (FST), but behaved as WT mice in response to acute citalopram in the FST. However, the effects of fluoxetine were blunted in Htr3a KO mice in these same tests. In an in vitro electrophysiological paradigm, a low-dose citalopram treatment triggered 5-HT receptor desensitization only in the dorsal raphe nucleus of Htr3a KO, although a high dose desensitized 5-HT autoreceptor function equally in Htr3a KO and WT mice, suggesting that citalopram may become effective at lower doses when 5-HT receptors are inactivated. In addition, Htr3a deletion blocked CSDS-induced modification in the cortical expression of two genes involved in oxidative stress, CaMKIIa and SOD1.
Taken together, these data show that Htr3a deletion promotes SSRI efficacy and prevents the occurrence of stress-induced deleterious effects, suggesting that the 5-HT receptor may represent an interesting target for the treatment of stress-related disorders.
最近有研究表明,5-羟色胺(5-HT)受体阻断可增强选择性5-羟色胺(血清素)再摄取抑制剂(SSRI)类抗抑郁药的疗效,并可能逆转啮齿动物应激诱导的缺陷。
为进一步探究这一假说,我们使用缺乏5-HT受体的小鼠(Htr3a基因敲除小鼠)及其野生型(WT)对照,评估它们在与焦虑和抑郁相关行为范式中的反应。对小鼠在基础状态、抗抑郁药治疗及慢性社会挫败应激(CSDS)条件下进行研究。
在基础状态下,Htr3a基因敲除小鼠在高架十字迷宫、社交互动及强迫游泳试验(FST)中表现出抗焦虑和抗抑郁样行为,但在FST中对急性西酞普兰的反应与野生型小鼠相同。然而,在这些相同试验中,氟西汀对Htr3a基因敲除小鼠的作用减弱。在体外电生理范式中,低剂量西酞普兰治疗仅在Htr3a基因敲除小鼠的中缝背核引发5-HT受体脱敏,而高剂量在Htr3a基因敲除小鼠和野生型小鼠中同等程度地使5-HT自身受体功能脱敏,这表明当5-HT受体失活时,西酞普兰可能在较低剂量时就变得有效。此外,Htr3a基因缺失阻断了CSDS诱导的参与氧化应激的两个基因CaMKIIa和SOD1在皮质表达的改变。
综上所述,这些数据表明Htr3a基因缺失可提高SSRI疗效并预防应激诱导的有害效应的发生,提示5-HT受体可能是治疗应激相关疾病的一个有意义的靶点。